Angela Ziebarth

Peer-Reviewed Publications

Ziebarth AJ, Felder MA, Harter J, Connor JP. Uterine leiomyosarcoma diffusely expresses disialoganglioside GD2 and binds the therapeutic immunocytokine 14.18-IL2: implications for immunotherapy. Cancer Immunol Immunotherapy. 2012, May 6. PMID 22562378

Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK,

Conner MB, Yang ES, Landen CN Jr Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clin Cancer Res. 2012 Nov 12. PMID 23147994

Steg AD, Katre AA, Bevis KS, Ziebarth AJ, Dobbin ZC, Shah MM, Alvarez RD, Landen CN. Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer. Molecular Cancer Therapeutics. 2012, May 2. PMID 22553355

Ziebarth AJ, Smith H, Killian ME, Nguyen NA, Durst JK, Subramaniam A, Kim KH, Leath CA 3rd, Straughn JM Jr, Alvarez RD. Completed versus aborted radical hysterectomy for node-positive stage IB cervical cancer in the modern era of chemoradiation therapy. Gynecol Oncol. Accepted 2012 Apr 5. PMID 22484400

Ziebarth AJ, Landen CN Jr, Alvarez RD. Molecular/Genetic therapies in ovarian cancer: future opportunities and challenges. Clin Obstet Gynecol. 2012 Mar;55(1):156-72. PMID 22343235

Steg AD, Bevis KS, Katre AA, Ziebarth AJ, Dobbin ZC, Alvarez RD, Zhang K, Conner M, Landen CN.Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Canc Research. 2012 Feb 1;18(3):869-81. PMID 22142828

Ziebarth AJ, Eyster K, Hansen K. Delayed Diagnosis of a Partially Obstructed Longitudinal Vaginal Septum. Fertil Steril. 2007. Mar;87(3):697.e17-20. PMID 17140575

Ziebarth AJ, Hansen KA. Hormonal Emergency Contraception: a clinical primer. SD Med. 2007. Mar;60(3):99-105. PMID 17455578

Textbook Chapters
Ziebarth A, Kim K, Huh W. Cervical Cancer. Gynecologic Oncology: Clinical Practice and Surgical Atlas. 2012. Ed. Karlan, Bristow and Li.

Oral Presentations at National Meetings
Ziebarth A, Steg A, Katre A, Shah M, Zhang K, Nowsheen S, Yang S, Conner M, Berestein W. Sood A, Landen C. Targeting Endoglin (CD105) induces apoptosis, improves platinum sensitivity both in vivo and in vitro, and is a potential therapeutic target in epithelial ovarian cancer. 9th Annual International Ovarian Cancer Symposium. 12/3/2011.

Onujiogu N, Ziebarth A, Felder M, Kapur A, Connor, J. High Ascites DcR3 levels are Associated with Poor Tumor Infiltration by CD8+ Lymphocytes in Advanced Ovarian Cancer. Annual Meeting of Western Association of Gynecologic Oncologists 6/10/2010.

Bradford L, Ziebarth A, Felder M, Kapur A, Connor, J. Ascites DcR3 Level is Associated with Poor Prognosis in Advanced Ovarian Cancer. Annual Meeting of Western Association of Gynecologic Oncologists 6/14/2009.

Posters Presented at National Meetings
Williams B, Ziebarth A, Burns, J. Uterine Carcinosarcoma as a Cancer Cluster. Annual Meeting of the American Congress of Obstetricians and Gynecologists, 5/7/2017

Antonetti A, Williams B, Ziebarth A, DeCesare S. Use of Phenazopyridine in Visualizing Ureteral Jet Stream During Cystoscopy. Annual Meeting of the American Congress of Obstetricians and Gynecologists, 5/7/2016

Ziebarth A, Dobbin Z, Katre A, Steg A, Alvarez R, Conner M, Landen C. Primary ovarian cancer murine xenografts maintain tumor heterogeneity and biologically correlate with patient response to primary chemotherapy. Annual Meeting of the Society of Gynecologic Oncologists, 3/24/2012.

Kim K, Gunn D, Smith H, Ziebarth A, Huh W. Cervical cancer in women 25 years and younger: An entirely different disease. Annual Meeting of the Society of Gynecologic Oncologists, 3/24/2012.

Ziebarth A, Steg A, Bevis K, Katre A, Nowsheen S, Sood A, Han M, Conner E, Yang E, Landen C. A novel role for the TGF-B co-receptor endoglin (CD105) in platinum resistant epithelial ovarian cancer. Annual Meeting of the Society of Gynecologic Oncologists, 3/24/2012.

Onujiogu N, Felder M, Kapur A, Ziebarth A, Connor, J. Decoy receptor 3 (DcR3) inhibits intratumoral lymphocytic infiltration by inhibiting Gm induced chemokine production in ovarian cancer. Annual Meeting of the Society of Gynecologic Oncologists, 3/24/2012.

Ziebarth A, Zheng H, Bradley A, Sakati W, Eier S, Lopez-Berestein S, Sood A, Eblen S, Landen C. The ubiquitin ligase EDD mediates platinum resistance and is a target for therapy in epithelial ovarian cancer. Featured Poster, Annual Meeting of the Society of Gynecologic Oncologists, 3/6/2011.

Ziebarth A, Steg A, Bevis K, Alvarez R, Landen C. Targeting the Hedgehog pathway reverses taxane resistance in ovarian cancer. Annual Meeting of the Society of Gynecologic Oncologists, 3/6/2011.

Ziebarth A, Durst J, Subramaniam A, Nguyen N, Smith H, Killian E, Kim K, Leath C, Straughn J. Alvarez R. Completed versus aborted radical hysterectomy for node positive stage I cervical cancer. Annual Meeting of the Society of Gynecologic Oncologists, 3/6/2011.

Morris, D. Ziebarth A, Kosuge H, O’Neill A, McConnell M, Landen C, Bellis S, Douglas T, Prevelige P. Virus Capsids as Targeted Nanoparticle Drug Delivery Systems. Gordan Kenan Physical Virology Conference, 2/15/2011.

Ziebarth A, Felder M, Harter J, Connor J. Uterine Leiomyosarcoma Express Disialoganglioside GD2 and Bind Immunocytokine 14.18 IL2; Implications for Immunotherapy. Annual Meeting of Western Association of Gynecologic Oncologists 6/13/2009.